Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 7:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 160 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: sofosbuvir Clear all
Terminated Phase 4 Interventional Results available

Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment

NCT03207399
View directory record Official record
Conditions
Hepatitis C, Chronic, Lung Transplant
Interventions
Epclusa
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 27, 2026, 7:20 PM EDT
Completed Phase 4 Interventional Results available

Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection

NCT03512210
View directory record Official record
Conditions
Hepatitis C, HIV-1-infection, Liver Diseases
Interventions
Sofosbuvir/Velpatasvir (SOF/VEL), Minimal Monitoring (MINMON) Strategy
Drug · Other
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 27, 2026, 7:20 PM EDT
No Longer Available No phase listed Expanded access

A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C

NCT02161939
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Daclatasvir (BMS-790052), Sofosbuvir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 27, 2026, 7:20 PM EDT
Completed Phase 4 Interventional Results available

Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant

NCT03619837
View directory record Official record
Conditions
Hepatitis C, Transplantation Disease Transmission
Interventions
Sofosbuvir/Velpatasvir, Sofosbuvir/Velpatasvir/Voxilaprevir
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 27, 2026, 7:20 PM EDT
Not listed Phase 4 Interventional

Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease

NCT02691728
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
LDV/SOF FDC
Drug
Lead sponsor
Peter J. Ruane, M.D., Inc.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Oct 27, 2026, 7:20 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy

NCT02607800
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF/VEL/VOX, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
47
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 27, 2026, 7:20 PM EDT
Terminated Phase 4 Interventional Results available

Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

NCT05717400
View directory record Official record
Conditions
Liver Cancer
Interventions
Bevacizumab, Atezolizumab, Sofosbuvir, Velpatasvir, Voxilaprevir, Ribavirin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 27, 2026, 7:20 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Utilization of Hepatitis C Positive Kidneys in Negative Recipients

NCT03801707
View directory record Official record
Conditions
Kidney Transplant, Hepatitis C, HCV
Interventions
Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 27, 2026, 7:20 PM EDT
Completed Phase 4 Interventional Results available

Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia

NCT02339038
View directory record Official record
Conditions
HCV HIV
Interventions
Ledipasvir 90 mg and Sofosbuvir 400 mg
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 27, 2026, 7:20 PM EDT
Completed Phase 3 Interventional Results available

Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon

NCT01542788
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
SOF, RBV, Placebo to match SOF, Placebo to match RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
50
States / cities
Birmingham, Alabama • Coronado, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 27, 2026, 7:20 PM EDT
Completed Phase 2 Interventional Results available

The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients

NCT03819322
View directory record Official record
Conditions
Liver Transplant, Hepatitis C
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Fernanda P Silveira, MD, MS
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 27, 2026, 7:20 PM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

NCT01938430
View directory record Official record
Conditions
Chronic HCV Infection
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
30
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 27, 2026, 7:20 PM EDT
Active, not recruiting Phase 2 Interventional

The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients

NCT03809533
View directory record Official record
Conditions
Kidney Transplantation, Hepatitis C
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Amit D Tevar, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 27, 2026, 7:20 PM EDT
Terminated Phase 2 Interventional Results available

Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C

NCT01532908
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
MBL-HCV1, Telaprevir (Part 1), Sofosbuvir (Part 2)
Biological · Drug
Lead sponsor
MassBiologics
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 27, 2026, 7:20 PM EDT
Completed Phase 4 Interventional Results available

Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection

NCT03057847
View directory record Official record
Conditions
Hepatitis C, Chronic, Opioid-use Disorder
Interventions
Sofosbuvir/Velpatasvir
Drug
Lead sponsor
Elizabeth Krans, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 27, 2026, 7:20 PM EDT
Completed Phase 2 Interventional Results available

Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3

NCT01808248
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF, PEG, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Oct 27, 2026, 7:20 PM EDT
Not yet recruiting Phase 4 Interventional

AI-Powered Hepatitis C Single-Encounter Test-and-Treat

NCT07793643
View directory record Official record
Conditions
HEPATITIS C (HCV)
Interventions
Epclusa (sofosbuvir and velpatasvir)
Drug
Lead sponsor
Patrick Grace
Other
Eligibility
22 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 27, 2026, 7:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients

NCT02743897
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Zepatier, Mavyret
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 27, 2026, 7:20 PM EDT
Completed Not applicable Interventional Results available

HCV Seek, Test and Rapid Treatment for Young PWID

NCT03627546
View directory record Official record
Conditions
Hepatitis C, Drug Use
Interventions
Rapid Treatment strategy, Usual Care (facilitated referral)
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 29 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 27, 2026, 7:20 PM EDT
Terminated Phase 3 Interventional Results available

Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis

NCT02455167
View directory record Official record
Conditions
Hepatitis C
Interventions
Simeprivir (SMV), Sofosbuvir (SOF), Ribavirin (RBV)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 27, 2026, 7:20 PM EDT
Completed Phase 2 Interventional Results available

Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis

NCT02994056
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Tampa, Florida • Chicago, Illinois • Catonsville, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 27, 2026, 7:20 PM EDT
Completed Phase 2 Interventional Results available

Combination Therapy for Chronic Hepatitis C Infection

NCT01805882
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Sofosbuvir, Ledipasvir, GS-9669, GS-9451
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 27, 2026, 7:20 PM EDT
Completed Phase 3 Interventional Results available

A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection

NCT02673489
View directory record Official record
Conditions
Hepatitis C
Interventions
DCV, SOF, RBV
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Marietta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 27, 2026, 7:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

GS-7977 With Ribavirin for Hepatitis C (SPARE)

NCT01441180
View directory record Official record
Conditions
Hepatitis C
Interventions
GS7977, RBV
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2014 · Synced Oct 27, 2026, 7:20 PM EDT